Personalized mRNA vaccine cuts melanoma recurrence by 42%
In the Phase 3 INTerpath-001 trial of 1,137 patients, adding the personalized mRNA vaccine intismeran autogene to standard pembrolizumab immunotherapy after surgery reduced the risk of melanoma recurrence or death by 42%. Each vaccine is custom-tailored by sequencing a patient’s tumor to encode up to 34 specific abnormal proteins. At two years post-treatment, 82.2% of patients receiving the combined regimen remained completely disease-free compared to 70% receiving immunotherapy alone. The trial marks the largest Phase 3 validation to date of individualized mRNA cancer vaccines.
EurekAlert! · October 24, 2026
Read on The Whole Day →